Log in

Medifast Stock Price, News & Analysis (NYSE:MED)

$102.00
+2.28 (+2.29 %)
(As of 10/17/2019 04:57 AM ET)
Today's Range
$99.50
Now: $102.00
$102.50
50-Day Range
$96.28
MA: $102.39
$109.06
52-Week Range
$95.10
Now: $102.00
$219.99
Volume154,900 shs
Average Volume273,283 shs
Market Capitalization$1.21 billion
P/E Ratio22.08
Dividend Yield3.01%
Beta0.69
Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. Read More…

Industry, Sector and Symbol

Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
CUSIP58470H10
Phone410-581-8042

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$501 million
Cash Flow$5.34 per share
Book Value$9.12 per share

Profitability

Net Income$55.79 million

Miscellaneous

Employees420
Market Cap$1.21 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.


Medifast (NYSE:MED) Frequently Asked Questions

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a -- dividend on Friday, September 13th. Investors of record on Friday, September 27th will be given a dividend of $0.75 per share on Thursday, November 7th. This represents a dividend yield of 2.8%. The ex-dividend date is Thursday, September 26th. View Medifast's Dividend History.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) posted its quarterly earnings data on Thursday, August, 1st. The specialty retailer reported $1.75 EPS for the quarter, topping the Zacks' consensus estimate of $1.71 by $0.04. The specialty retailer had revenue of $187.10 million for the quarter, compared to the consensus estimate of $181.74 million. Medifast had a net margin of 11.22% and a return on equity of 61.06%. The firm's quarterly revenue was up 59.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.16 earnings per share. View Medifast's Earnings History.

When is Medifast's next earnings date?

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Medifast.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $6.75-$6.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.78. The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $738.02 million.

What price target have analysts set for MED?

3 equities research analysts have issued twelve-month target prices for Medifast's stock. Their forecasts range from $130.00 to $250.00. On average, they expect Medifast's stock price to reach $198.67 in the next twelve months. This suggests a possible upside of 94.8% from the stock's current price. View Analyst Price Targets for Medifast.

What is the consensus analysts' recommendation for Medifast?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Has Medifast been receiving favorable news coverage?

News coverage about MED stock has been trending very negative on Thursday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medifast earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Medifast.

Are investors shorting Medifast?

Medifast saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,390,000 shares, an increase of 17.3% from the August 30th total of 2,890,000 shares. Based on an average daily trading volume, of 316,800 shares, the short-interest ratio is currently 10.7 days. Approximately 29.7% of the company's stock are sold short. View Medifast's Current Options Chain.

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Boeing (BA), UnitedHealth Group (UNH), Micron Technology (MU), Paypal (PYPL), Mastercard (MA), Align Technology (ALGN), Adobe (ADBE), Lululemon Athletica (LULU) and Alibaba Group (BABA).

Who are Medifast's key executives?

Medifast's management team includes the folowing people:
  • Mr. Daniel R. Chard, CEO & Director (Age 54)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
  • Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

Who are Medifast's major shareholders?

Medifast's stock is owned by many different of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (0.49%), Chickasaw Capital Management LLC (0.28%), State of Alaska Department of Revenue (0.08%) and First Hawaiian Bank (0.04%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.

Which institutional investors are buying Medifast stock?

MED stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, First Hawaiian Bank, Chickasaw Capital Management LLC and Ingalls & Snyder LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $102.00.

How big of a company is Medifast?

Medifast has a market capitalization of $1.21 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.

What is Medifast's official website?

The official website for Medifast is http://www.medifast1.com/.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]


MarketBeat Community Rating for Medifast (NYSE MED)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  633
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel